Access to New Therapy Areas to Drive Major Growth in the Global Biosimilars Market, 2020–2026

Access to New Therapy Areas to Drive Major Growth in the Global Biosimilars Market, 2020–2026

Outsourced Manufacturing of the Complex Third Wave of Biosimilars to Spark New Growth Opportunities

RELEASE DATE
23-Oct-2020
REGION
North America
Research Code: MF9D-01-00-00-00
SKU: HC03328-GL-MT_24670

$4,950.00

Special Price $4,207.50 save 15 %

In stock
SKU
HC03328-GL-MT_24670

$4,950.00

$4,207.50 save 15 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

In this research service, the Transformational Health team at Frost & Sullivan provides critical insights into the global biosimilar industry, highlighting the key growth opportunities, market revenue forecasts, and trends that will influence the industry with the emergence of the third wave of biosimilars. The global third-wave biosimilars market covered in this study includes a discussion of antibody therapies and recombinant proteins. It also includes a market forecast for the third wave biosimilars till 2026, capturing the interesting developments and market dynamic shifts that are set to influence the growth of industry stakeholders.

This study identifies the largest revenue-generating therapeutic areas and drug types, and the year with the highest market revenue potential for biosimilar companies based on biologics patent expiry. Market entry considerations for biosimilar companies and factors influencing global biosimilar penetration have been clearly outlined. This research service also provides comprehensive insights on the complex dynamics that are set to influence the third wave of biosimilars, such as the re-imbursement and the payer landscape, biosimilar pricing trends, and the various sales models that are prevalent in the biosimilars industry. Regional differences in terms of biosimilar pricing have also been discussed in this study in addition to the challenges relevant to the industry such as physicians’ acceptance of biosimilars, manufacturing complexities, and patent litigations. Most importantly, this study highlights the competitive landscape for the third wave of biosimilars, providing the different approaches taken by innovator companies to fight biosimilar competition. Finally, with this research service, Frost & Sullivan’s Transformational Health team delineates the key growth opportunities that can help increased biosimilar uptake, overcome manufacturing complexities, handle biobetter innovations, and leverage advantages in competing for newer therapy areas, such as ophthalmology.


Research Highlights

  • Market revenue forecast for the third-wave biosimilars market, 2020-2026
  • Segment-wise revenue forecast by therapeutic area and drug type
  • Competitive landscape analysis of the third-wave biosimilars market
  • Market dynamics influencing the third-wave biosimilars market
  • Growth opportunities in the global biosimilars market
  • Strategic imperatives for the global biosimilars market

Key Issues Addressed?

  • What will be the market revenue of the global third-wave biosimilars market from 2020 to 2026?
  • Which therapy areas and patent expiry years of biologics are likely to influence this market?
  • What are the key trends that will influence the industry during the forecast period?
  • How does the third-wave biosimilars competitive landscape look like?
  • What are the major growth opportunities in the global biosimilars industry? 

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Why Is It Increasingly Difficult to Grow?

The Strategic Imperative 8™

Strategic Imperatives for the Global Biosimilars Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Scope of Analysis

Biosimilars in the Perspective of Regulatory Bodies

Key Differences between Biosimilars, Biologics, and Biobetters

Focus of Study: The Third Wave of Biosimilars

Market Segmentation by Product

Key Competitors in the Global Biosimilars Market

Key Growth Metrics for the Third-wave Biosimilars Market

Distribution Channels Adopted by Biosimilar Companies

Market Entry Considerations for Biosimilars

Factors Affecting Global Penetration of Biosimilars

4 Key Developments in the Re-imbursement and Payer Landscape

Regulatory Changes That Have Influenced The Biosimilar Market

Growth Drivers for the Global Biosimilars Market

Growth Restraints for Global Biosimilars Market

Forecast Methodology and Assumptions—Third-wave Biosimilars Market

Total Third-wave Biosimilars Market

Market Forecast Analysis, 2020–2026 (Total Third-wave Biosimilars Market)

Forecast by Drug Type: Antibody Therapies vs. Recombinant Proteins

Market Forecast Analysis, 2020–2026 (by Drug Type)

Forecast by Therapy Area—Third-wave Biosimilars Market

Forecast of Third-wave Biosimilars—By Year-wise Patent-expiry of Biologics

Market Forecast Analysis, 2020–2026 (By Therapy Area and Year-wise patent expiry of Biologics)

Regional Analysis—Global Biosimilars Market

Regional Analysis of Factors Impacting Biosimilars Market Access

Regional Analysis Discussion

Pricing Trends—US Biosimilars Market

Pricing Trends—Western Europe Biosimilars Market

Competitive Environment—Global Biosimilars Market

Companies to Action

Impact of Third-wave Biosimilars on the Competitive Landscape

Case Study: AbbVie—Delaying Biosimilar Competition

Major Growth Opportunities

Growth Opportunity 1: Manufacturing Outsourcing Collaborations for Complex Third-wave Biosimilars, 2020

Growth Opportunity 1: Manufacturing Outsourcing Collaborations for Complex Third-wave Biosimilars, 2020 (continued)

Growth Opportunity 1: Manufacturing Outsourcing Collaborations for Complex Third-wave Biosimilars, 2020 (continued)

Growth Opportunity 2: Increased Market Access Through Biobetter Innovations For Biosimilar Companies, 2020

Growth Opportunity 2: Increased Market Access Through Biobetter Innovations For Biosimilar Companies, 2020 (continued)

Growth Opportunity 2: Increased Market Access Through Biobetter Innovations For Biosimilar Companies, 2020 (continued)

Growth Opportunity 2: Increased Market Access Through Biobetter Innovations For Biosimilar Companies, 2020 (continued)

Growth Opportunity 3: Developing and Manufacturing of Biosimilars in India for the Global Market, 2020

Growth Opportunity 3: Developing and Manufacturing of Biosimilars in India for the Global Market, 2020 (continued)

Growth Opportunity 4: Interchangeability Approvals for Increased Biosimilar Uptake in the US Market, 2020

Growth Opportunity 4: Interchangeability Approvals for Increased Biosimilar Uptake in the US Market, 2020 (continued)

Growth Opportunity 5: Ophthalmology Biosimilars for First-to-Market Advantage, 2020

Growth Opportunity 5: Ophthalmology Biosimilars for First-to-market Advantage, 2020 (continued)

Growth Opportunity 5: Ophthalmology Biosimilars for First-to-market Advantage, 2020 (continued)

Growth Opportunity 5: Ophthalmology Biosimilars for First-to-market Advantage, 2020 (continued)

Your Next Steps

Why Frost, Why Now?

List of Exhibits

List of Exhibits (continued)

Legal Disclaimer

Related Research
In this research service, the Transformational Health team at Frost & Sullivan provides critical insights into the global biosimilar industry, highlighting the key growth opportunities, market revenue forecasts, and trends that will influence the industry with the emergence of the third wave of biosimilars. The global third-wave biosimilars market covered in this study includes a discussion of antibody therapies and recombinant proteins. It also includes a market forecast for the third wave biosimilars till 2026, capturing the interesting developments and market dynamic shifts that are set to influence the growth of industry stakeholders. This study identifies the largest revenue-generating therapeutic areas and drug types, and the year with the highest market revenue potential for biosimilar companies based on biologics patent expiry. Market entry considerations for biosimilar companies and factors influencing global biosimilar penetration have been clearly outlined. This research service also provides comprehensive insights on the complex dynamics that are set to influence the third wave of biosimilars, such as the re-imbursement and the payer landscape, biosimilar pricing trends, and the various sales models that are prevalent in the biosimilars industry. Regional differences in terms of biosimilar pricing have also been discussed in this study in addition to the challenges relevant to the industry such as physicians’ acceptance of biosimilars, manufacturing complexities, and patent litigations. Most importantly, this study highlights the competitive landscape for the third wave of biosimilars, providing the different approaches taken by innovator companies to fight biosimilar competition. Finally, with this research service, Frost & Sullivan’s Transformational Health team delineates the key growth opportunities that can help increased biosimilar uptake, overcome manufacturing complexities, handle biobetter innovations, and leverage advantages in competing for newer therapy areas, such as ophthalmology.--BEGIN PROMO--

Research Highlights

  • Market revenue forecast for the third-wave biosimilars market, 2020-2026
  • Segment-wise revenue forecast by therapeutic area and drug type
  • Competitive landscape analysis of the third-wave biosimilars market
  • Market dynamics influencing the third-wave biosimilars market
  • Growth opportunities in the global biosimilars market
  • Strategic imperatives for the global biosimilars market

Key Issues Addressed

  • What will be the market revenue of the global third-wave biosimilars market from 2020 to 2026?
  • Which therapy areas and patent expiry years of biologics are likely to influence this market?
  • What are the key trends that will influence the industry during the forecast period?
  • How does the third-wave biosimilars competitive landscape look like?
  • What are the major growth opportunities in the global biosimilars industry? 

Author: Deepak Jayakumar

More Information
No Index No
Podcast No
Author Deepak Jayakumar
Industries Healthcare
WIP Number MF9D-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,9571-B1,99C1-B1,9568-B1,9611-B1